Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its extensive supply chain?

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and challenges as it positions itself for long-term growth. Recent financial reports and analyst assessments paint a picture of a company leveraging its strong oncology portfolio and innovative medicine segment to offset headwinds in other areas.

Michigan is in need of additional help in the secondary heading into the 2025 season. Will Johnson and Aamir Hall are both gone at corner, and so are Makari Pai

Whether Ben Johnson and Ryan Poles think it's a top priority isn't known but the new Bears coach threw out a position they could stand to 'augment.'

Ben Johnson doesn't need clichés to get his point across, nor does he want anything that he didn't earn. He's the right guy for the Chicago Bears. What's better is that he knows it, too.

We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said. “That’s what individuals who stoke fear into people want to see happen.”

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.